Use of Salbutamol with Budesonide in Infants Under 1 Year with Wheezing

Evidence Supporting Combined Use

The American Academy of Allergy, Asthma, and Immunology recommends that budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions in the same nebulizer 1
Budesonide is the only inhaled corticosteroid (ICS) with FDA-approved labeling for children under 4 years of age, as stated by the American Academy of Pediatrics 1, 2

For infants under 1 year with wheezing, the recommended dose of albuterol (salbutamol) nebulizer solution is 0.63 mg/3 mL, as suggested by the American Academy of Allergy, Asthma, and Immunology 3
The recommended dose of budesonide nebulizer suspension is 0.25-0.5 mg (low daily dose), which can be increased to >0.5-1.0 mg for medium daily dosing if needed, according to the American Academy of Allergy, Asthma, and Immunology 1, 2

For children under 4 years of age, delivery requires a face mask that should fit snugly over nose and mouth, as recommended by the American Academy of Pediatrics 2
The American Academy of Allergy, Asthma, and Immunology advises to avoid nebulizing in the eyes and to wash face after each treatment to prevent local side effects 2, 1
Only jet nebulizers should be used because ultrasonic nebulizers are ineffective for suspensions, as stated by the American Academy of Allergy, Asthma, and Immunology 1

The safety and efficacy of inhaled corticosteroids in children under 1 year has not been fully established, requiring careful monitoring, as recommended by the American Academy of Pediatrics 1
Potential local side effects include cough, dysphonia, and oral thrush (candidiasis), according to the American Academy of Allergy, Asthma, and Immunology 2

The American Academy of Allergy, Asthma, and Immunology recommends assessing the severity of wheezing and respiratory distress 4
For recurrent or persistent wheezing, consider regular budesonide treatment alongside as-needed salbutamol, as suggested by the American Thoracic Society 5, 4
Monitor response carefully; if no clear benefit is observed within 4-6 weeks, consider alternative therapies or diagnoses, as recommended by the American Academy of Allergy, Asthma, and Immunology 4, 6